









Markets
/
Stocks
/
nasdaq-ibrx
/

Immunitybio Inc

IBRX

2.140USD

-0.020-0.93%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

2.11BMarket Cap

LossP/E TTM



Immunitybio Inc

2.140

-0.020-0.93%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Immunitybio Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immunitybio Inc's Score

Industry at a Glance

Industry Ranking

79 / 407

Overall Ranking

200 / 4611

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

10.200

Target Price

+378.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Immunitybio Inc Highlights

StrengthsRisks

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 6043.75% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 14.74M.

Undervalued

The company’s latest PE is -5.42, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 133.12M shares, increasing 22.46% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 36.34K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 8.24, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 32.06M, representing a year-over-year increase of 425.07%, while its net profit experienced a year-over-year increase of 21.55%.

Score

Industry at a Glance

Previous score

8.24

Change



Financials

5.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.12

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Immunitybio Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 6.22, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -5.42, which is -78.97% below the recent high of -1.14 and -57.26% above the recent low of -8.52.

Score

Industry at a Glance

Previous score

6.22

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 79/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.80, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Immunitybio Inc is 8.00, with a high of 24.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

10.200

Target Price

+372.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Immunitybio Inc

IBRX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 6.49, which is lower than the Biotechnology & Medical Research industry's average of 6.59. Sideways: Currently, the stock price is trading between the resistance level at 2.55 and the support level at 1.88, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.59

Change

-0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.054

Sell

RSI(14)

38.375

Neutral

STOCH(KDJ)(9,3,3)

26.328

Neutral

ATR(14)

0.129

High Vlolatility

CCI(14)

-81.153

Neutral

Williams %R

79.104

Sell

TRIX(12,20)

-0.576

Sell

StochRSI(14)

66.750

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.140

Buy

MA10

2.222

Sell

MA20

2.354

Sell

MA50

2.471

Sell

MA100

2.532

Sell

MA200

2.702

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 13.51%, representing a quarter-over-quarter decrease of 82.71%. The largest institutional shareholder is The Vanguard, holding a total of 27.60M shares, representing 2.80% of shares outstanding, with 18.27% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cambridge Equities, L.P.

614.63M

+23.56%

Soon-Shiong (Patrick)

35.16M

The Vanguard Group, Inc.

Star Investors

21.76M

+7.17%

BlackRock Institutional Trust Company, N.A.

15.28M

+31.60%

BofA Global Research (US)

8.76M

+1522.59%

Armistice Capital LLC

7.76M

Jane Street Capital, L.L.C.

7.72M

+5866.36%

State Street Investment Management (US)

7.62M

+0.42%

Geode Capital Management, L.L.C.

5.78M

+34.69%

Woodline Partners LP

3.45M

+0.02%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 4.85, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -0.01. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.